Motilal Oswal has reiterated a 'Buy' rating for Rubicon Research, setting a target of Rs 1,915. The firm cites consistent earnings growth, including a 95.8% profit jump in the latest quarter. Investors are weighing this expansion against the stock's significant 166% year-to-date rally and rising working capital needs.
Motilal Oswal has reaffirmed its 'Buy' outlook on Rubicon Research, projecting a target price of Rs 1,915. This update follows a period of strong financial performance from the company, which has managed to beat earnings expectations for four consecutive quarters since its listing.
The latest results for the quarter ended June 30, 2026, highlight the growth momentum. Rubicon Research reported revenue of Rs 534 crore, marking a 51.6% increase compared to the previous year. Net profit saw an even sharper rise, climbing 95.8% to Rs 84.8 crore. Driven by these results, the company has updated its EBITDA margin guidance for the full fiscal year to at least 23%.
Margin Strategy and Operational Focus
The brokerage report points to a strategic pivot in the company's business model as a key driver for future profitability. Rubicon Research is actively moving away from lower-margin businesses, which has helped improve gross margins sequentially. By balancing its in-house manufacturing with outsourced operations, the company is aiming for greater efficiency. This strategy is expected to support a profit after tax growth rate of 33% through fiscal year 2028.
Risks and Market Valuation
While the outlook remains positive, investors are also considering specific risk factors. The stock has experienced a sharp run-up, rising over 166% in the calendar year 2026 to trade near Rs 1,808. This movement has pushed the company's valuation to approximately 23 times its book value, a level that investors often scrutinize for potential overextension.
Additionally, the company’s working capital cycle has lengthened, with days increasing from 68.8 to 104. This trend means that the company is taking longer to convert its business activities into cash, which could impact financial flexibility if it continues.
Future Monitorables
Looking ahead, the company’s ability to execute its expansion plans remains critical. The Pithampur manufacturing site, which underwent a USFDA inspection in June 2026, received two procedural observations. While the company prepares for a commercial ramp-up, the final success depends on timely regulatory approvals and the efficient commercialization of products in the US market. Investors will likely track the company's ability to maintain its margin guidance and stabilize its working capital levels in the coming quarters.